• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    11/14/24 5:52:18 PM ET
    $VRDN
    Medical Specialities
    Health Care
    Get the next $VRDN alert in real time by email
    SC 13G/A 1 tm2428137d19_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)*

     

    Viridian Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    92790C104

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

    CUSIP No. 92790C104 Page 2 of 14

     

             
    1.   Name of reporting persons
     
    Venrock Healthcare Capital Partners III, L.P.
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨  

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    PN
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

    CUSIP No. 92790C104 Page 3 of 14

     

             
    1.   Name of reporting persons
     
    VHCP Co-Investment Holdings III, LLC
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x  (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨  

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    OO
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

    CUSIP No. 92790C104 Page 4 of 14

     

             
    1.   Name of reporting persons
     
    Venrock Healthcare Capital Partners EG, L.P.
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x  (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨  

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    PN
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

     CUSIP No. 92790C104 Page 5 of 14

     

             
    1.   Name of reporting persons
     
    VHCP Management III, LLC
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    OO
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

    CUSIP No. 92790C104 Page 6 of 14

     

             
    1.   Name of reporting persons
     
    VHCP Management EG, LLC
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x  (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ 

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    OO
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

    CUSIP No. 92790C104 Page 7 of 14

     

             
    1.   Name of Reporting Persons
     
    Shah, Nimish
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x  (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ 

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    IN
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

    CUSIP No. 92790C104 Page 8 of 14

     

             
    1.   Name of Reporting Persons
     
    Koh, Bong
    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) x (1)

    (b) ¨

    3.   SEC USE ONLY
     
    4.   Citizenship or Place of Organization
     
    United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5.   Sole Voting Power
     
    0
    6.   Shared Voting Power
     
    3,575,309 (2)
    7.   Sole Dispositive Power
     
    0
    8.   Shared Dispositive Power
     
    3,575,309 (2)
    9.   Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,575,309 (2)
    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ 

     

    11.   Percent of Class Represented by Amount in Row (9)
     
    5.5% (3)
    12.   Type of Reporting Person (See Instructions)
     
    IN
                    

    (1)This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P. (“VHCP-EG”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), VHCP Management EG, LLC (VHCPM-EG”), the general partner of VHCP-EG, Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the “Reporting Persons.”). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    (3)This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer’s common stock outstanding as of August 5, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons.

     

       

     

     

    CUSIP No. 92790C104 Page 9 of 14

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-EG” and together with VHCP III, VHCP-III Co-Invest, VHCP EG and VHCPM-III, the “Venrock Entities”)), Nimish Shah (“Shah”) and Bong Koh (“Koh” and together with the Venrock Entities and Shah, the “Reporting Persons”) in respect of Common Stock of Viridian Therapeutics, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Viridian Therapeutics, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    221 Crescent Street, Suite 401

    Waltham, MA 02453

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.01 per share

     

      (e) CUSIP Number

     

    92790C104

     

       

     

     

    CUSIP No. 92790C104 Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   3,575,309 (1)
    VHCP Co-Investment Holdings III, LLC   3,575,309 (1)
    Venrock Healthcare Capital Partners EG, L.P.   3,575,309 (1)
    VHCP Management III, LLC   3,575,309 (1)
    VHCP Management EG, LLC   3,575,309 (1)
    Nimish Shah   3,575,309 (1)
    Bong Koh   3,575,309 (1)

     

      (b) Percent of Class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   5.5%
    VHCP Co-Investment Holdings III, LLC   5.5%
    Venrock Healthcare Capital Partners EG, L.P.   5.5%
    VHCP Management III, LLC   5.5%
    VHCP Management EG, LLC   5.5%
    Nimish Shah   5.5%
    Bong Koh   5.5%

     

      (c) Number of shares as to which the person has, as of September 30, 2024:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

       

     

     

    CUSIP No. 92790C104 Page 11 of 14

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners III, L.P.   3,575,309 (1)
    VHCP Co-Investment Holdings III, LLC   3,575,309 (1)
    Venrock Healthcare Capital Partners EG, L.P.   3,575,309 (1)
    VHCP Management III, LLC   3,575,309 (1)
    VHCP Management EG, LLC   3,575,309 (1)
    Nimish Shah   3,575,309 (1)
    Bong Koh   3,575,309 (1)

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners III, L.P.   3,575,309 (1)
    VHCP Co-Investment Holdings III, LLC   3,575,309 (1)
    Venrock Healthcare Capital Partners EG, L.P.   3,575,309 (1)
    VHCP Management III, LLC   3,575,309 (1)
    VHCP Management EG, LLC   3,575,309 (1)
    Nimish Shah   3,575,309 (1)
    Bong Koh   3,575,309 (1)

     

    (1)Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

      

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

       

     

     

    CUSIP No. 92790C104 Page 12 of 14

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

       

     

     

    CUSIP No. 92790C104 Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management III, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: Manager
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
         
    VHCP Management III, LLC   VHCP Management EG, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.    
         
    By: VHCP Management EG, LLC    
    Its: General Partner    
         
    /s/ Sherman G. Souther    
    Name:   Sherman G. Souther    
    Its:   Authorized Signatory    

     

    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact

     

    Venrock Opportunities Fund, L.P.   Venrock Opportunities Management, LLC
             
    By: Venrock Opportunities Management, LLC   By: /s/ Sherman G. Souther
    Its: General Partner     Name: Sherman G. Souther
            Its: Authorized Signatory
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther        
      Its: Authorized Signatory        

     

       

     

     

    CUSIP No. 92790C104 Page 14 of 14

     

    EXHIBITS

     

    A: Joint Filing Agreement Shah (incorporated by reference to Exhibit A of Schedule 13G/A filed February 14, 2023)

     

    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B of Schedule 13G filed October 14, 2021)

     

    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C of Schedule 13G filed October 14, 2021)

     

       

     

    Get the next $VRDN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRDN

    DatePrice TargetRatingAnalyst
    12/19/2024$37.00 → $27.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024Buy
    TD Cowen
    9/11/2024$30.00 → $38.00Buy
    Needham
    6/11/2024$29.00Outperform
    Wolfe Research
    6/6/2024$23.00Buy
    Goldman
    5/9/2024Buy → Neutral
    Ladenburg Thalmann
    5/9/2024$25.00 → $20.00Buy → Neutral
    B. Riley Securities
    6/14/2023$51.00Outperform
    Credit Suisse
    More analyst ratings

    $VRDN
    Financials

    Live finance-specific insights

    See more
    • Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

      - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug

      12/16/24 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

      - THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta

      12/13/24 6:00:00 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

      - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r

      9/10/24 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

      - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

      5/6/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

      - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 20

      4/7/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

      - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter o

      2/27/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VRDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $VRDN
    SEC Filings

    See more

    $VRDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4 filed by Director Ajer Jeffrey Robert

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      4/9/25 4:26:02 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Ajer Jeffrey Robert

      3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      4/9/25 4:19:55 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      3/12/25 4:36:26 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Viridian Therapeutics from Overweight to Equal Weight and set a new price target of $27.00 from $37.00 previously

      12/19/24 8:33:15 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on Viridian Therapeutics

      TD Cowen initiated coverage of Viridian Therapeutics with a rating of Buy

      11/25/24 7:56:18 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Needham reiterated coverage on Viridian Therapeutics with a new price target

      Needham reiterated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $38.00 from $30.00 previously

      9/11/24 8:00:48 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Viridian Therapeutics Inc.

      10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      5/6/25 7:55:45 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      5/6/25 7:28:38 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Viridian Therapeutics Inc.

      DEFA14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      4/25/25 7:57:02 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 5:53:44 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 5:52:18 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 4:50:30 PM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

      - Breakthrough Therapy Designation request based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response - - Veligrotug met all of its primary and secondary endpoints in the pivotal THRIVE and THRIVE-2 clinical trials in active and chronic TED - - First and only drug candidate in chronic TED to demonstrate statistically significant and clinically meaningful improvement and resolution of diplopia in a global phase 3 clinical trial - - Breakthrough Therapy Designation supports eligibility for Priority Review - - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 wit

      5/7/25 4:15:00 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

      - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

      5/6/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company's common stock to 13 new employees (the "Inducement Grants") on May 1, 2025 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of

      5/2/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Beetham Thomas W. bought $117,050 worth of shares (5,000 units at $23.41), increasing direct ownership by 500% to 6,000 units (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/30/24 7:12:50 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • President and CEO Mahoney Stephen F. bought $499,262 worth of shares (21,400 units at $23.33) (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/30/24 7:10:58 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Director Fairmount Funds Management Llc bought $30,000,000 worth of shares (1,600,000 units at $18.75) (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/17/24 9:00:13 PM ET
      $VRDN
      Medical Specialities
      Health Care